Pharmacokinetics and safety of the anti-human cytomegalovirus drug letermovir in subjects with hepatic impairment

British Journal of Clinical Pharmacology

Volumn 83, Issue 12, 2017, Pages 2678-2686

  Kropeit, Dirk ^a   McCormick, David ^b   Erb Zohar, Katharina ^c   Moiseev, Valentin S ^d   Kobalava, Zhanna D ^d   Stobernack, Hans Peter ^a   Zimmermann, Holger ^a   Rübsamen Schaeff, Helga ^a  

^a AiCuris GmbH   (Germany)

^b DMPK Solutions Limited   (United Kingdom)

^c Clinphase   (Germany)

^d PEOPLES FRIENDSHIP UNIVERSITY OF RUSSIA   (Russian Federation)

Author keywords

antivirals; cytomegalovirus; hepatic insufficiency; letermovir; pharmacokinetics; terminase inhibitor

Indexed keywords

LETERMOVIR; ACETIC ACID DERIVATIVE; ANTIVIRUS AGENT; QUINAZOLINE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL ARTICLE; COMPARATIVE STUDY; CONCENTRATION AT STEADY-STATE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; ELIMINATION HALF-LIFE; ELIMINATION RATE CONSTANT; FEMALE; HEADACHE; HUMAN; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; MINIMUM PLASMA CONCENTRATION; MODERATE HEPATIC IMPAIRMENT; MORNING DOSAGE; OPEN STUDY; ORAL CLEARANCE; PHARMACOKINETIC PARAMETERS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SEVERE HEPATIC IMPAIRMENT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; UNBOUND FRACTION; VOLUME OF DISTRIBUTION AT STEADY-STATE; ADOLESCENT; AGED; BLOOD; CLINICAL TRIAL; DRUG ADMINISTRATION; HALF LIFE TIME; LIVER; LIVER DISEASE; METABOLIC CLEARANCE RATE; METABOLISM; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; RUSSIAN FEDERATION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

ACETATES; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; AREA UNDER CURVE; CYTOMEGALOVIRUS INFECTIONS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALF-LIFE; HUMANS; LIVER; LIVER DISEASES; METABOLIC CLEARANCE RATE; MIDDLE AGED; QUINAZOLINES; RUSSIA; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85028332400     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.13376     Document Type: Article

References (17)

1. Beam E, Razonable RR. Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment. Curr Infect Dis Rep 2012; 14: 633–641.
2. Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Infect Dis Clin North Am 2010; 24: 319–337.
3. Melendez DP, Razonable RR. Letermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirus. Infect Drug Resist 2015; 8: 269–277.
4. Jacobsen T, Sifontis N. Drug interactions and toxicities associated with the antiviral management of cytomegalovirus infection. Am J Health Syst Pharm 2010; 67: 1417–1425.
5. Salzberger B, Bowden RA, Hackman RC, Davis C, Boeckh M. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. Blood 1997; 90: 2502–2508.
6. Buerger I, Reefschlaeger J, Bender W, Eckenberg P, Popp A, Weber O, et al. A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products. J Virol 2001; 75: 9077–9086.
7. Reefschlaeger J, Bender W, Hallenberger S, Weber O, Eckenberg P, Goldmann S, et al. Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action. J Antimicrob Chemother 2001; 48: 757–767.
8. Zimmermann H, Lischka P, Ruebsamen-Schaeff H. Letermovir (AIC246) a novel drug under development for prevention and treatment of cytomegalovirus infections acting via a novel mechanism of action. Eur Infect Dis 2011; 5: 112–114.
9. Sullivan V, Talarico CL, Stanat SC, Davis M, Coen DM, Biron KK. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 1992; 359: 85.
10. Chemaly RF, Ullmann AJ, Stoelben S, Richard MP, Bornhäuser M, Groth C, et al. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med 2014; 370: 1781–1789.
11. Stoelben S, Arns W, Renders L, Hummel J, Muhlfeld A, Stangl M, et al. Preemptive treatment of cytomegalovirus infection in kidney transplant recipients with letermovir: results of a phase 2a study. Transpl Int 2014; 27: 77–86.
12. Marty FM, Ljungman PT, Chemaly RF, Maertens JA, Snydman DR, Duarte RF, et al. A phase III randomized, double-blind, placebo-controlled trial of letermovir (LET) for prevention of cytomegalovirus (CMV) infection in adult CMV-seropositive recipients of allogeneic hematopoietic cell transplantation (HCT). Paper presented at the BMT Tandem Meetings 2017, 2017.
13. Kaul DR, Stoelben S, Cober E, Ojo T, Sandusky E, Lischka P, et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant 2011; 11: 1079–1084.
14. European Medicines Agency. Evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function. Available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000370.jsp. Updated 2005 (last accessed 22 May 2017).
15. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SPH, et al. The IUPHAR/BPS guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucleic Acids Res 2016; 44: D1054–D1068.
16. Alexander SPH, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E, et al. The Concise Guide to PHARMACOLOGY 2015/16: Transporters. Br J Pharmacol 2015; 172: 6110–6202.
17. Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE, et al. The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 2015; 172: 6024–6109.